← back to search

Jenny M. Reimer

Novavax (Sweden) · SE
Area of research
Public Health, Environmental and Occupational Health · Immunology
Research interest
Research interests include Malaria Research and Control, Mosquito-borne diseases and control, Food Allergy and Anaphylaxis Research, and Mast cells and histamine.
h-index
16
citations
1,416
works
31
NIH funding
—
primary concept
Biology
email
✉ Find email ↗

Recent publications

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
The Lancet Infectious Diseases 2022cited by 283position: middledoi
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
The Lancet 2021cited by 456position: middledoi
Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice
Vaccine 2014cited by 31position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

— · 1 papers (2014–2014)— · 1 papers (2014–2014)Sebastian Ulbert · Fraunhofer Institute for Cell Therapy and Immunology1 papers (2014–2014)— · 1 papers (2014–2014)Luisa Barzon · University of Pavia1 papers (2014–2014)— · 1 papers (2014–2014)— · 1 papers (2014–2014)— · 1 papers (2014–2014)— · 1 papers (2014–2014)— · 1 papers (2014–2014)Justin M. Richner · University of Illinois Chicago1 papers (2014–2014)